Back
Sage Therapeutics 10K Form
Buy
56
SAGE
Sage Therapeutics
Last Price:
43.01
Seasonality Move:
9.88%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive SAGE News And Ratings
See the #1 stock for the next 7 days that we like better than SAGE
SAGE Financial Statistics
Sales & Book Value
| Annual Sales: | $7.69M |
|---|---|
| Cash Flow: | $-127.21M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $21.05 |
| Price / Book: | 2.05 |
Profitability
| EPS (TTM): | -8.98000 |
|---|---|
| Net Income (TTM): | $-532.78M |
| Gross Margin: | $6.87M |
| Return on Equity: | -35.59% |
| Return on Assets: | -33.4% |
Sage Therapeutics Earnings Forecast
Key Sage Therapeutics Financial Ratios
- The Gross Profit Margin over the past 10 years for SAGE is 89.34%.
- The Selling, General & Administrative Expenses for SAGE have been equal to 2,960.99% of Gross Profit Margin.
- The Research & Development expenses have been 4,241.35% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- Per Share Earnings over the last 11 years have been positive in 1 years.
Sage Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Current Symbol: | SAGE |
| CUSIP: | 78667J |
| Website: | sagerx.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 13.47 |
| Quick Ratio: | 12.96 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
SAGE Technical Analysis vs Fundamental Analysis
Buy
56
Sage Therapeutics (SAGE)
is a Buy
Is Sage Therapeutics a Buy or a Sell?
-
Sage Therapeutics stock is rated a Buy
The current Sage Therapeutics [SAGE] share price is $42.91. The Score for SAGE is 56, which is 12% above its historic median score of 50, and infers lower risk than normal.